

SUPPLEMENTARY TABLE 3

Long-acting medication comparison profiles as stated in the Canadian ADHD Resource Alliance (CADDRA) guidelines

Reproduced with permission from CADDRA

	Adderall XR	Vyvanse	Biphentin	Concerta	Novo-methylphenidate ER-C	Strattera	Intuniv XR
Clinical Comparisons							
Active ingredient	Mixed amphetamine salts	Dexamphetamine	Methylphenidate hydrochloride	Methylphenidate hydrochloride	Methylphenidate hydrochloride	Atomoxetine	Guanfacine extended-release
Clinical efficacy studies	Yes	Yes	Yes	Yes	No	Yes	Yes
Long-acting technology used	Two beads	Pro-drug	Multilayer beads	OROS	Unknown	Blood level based	Polymer matrix
Duration of effect*	~12 hours	13–14 hours	10–12 hours	10–12 hours	Unknown	Continuous	Continuous
(%IR/%LA) delivery	50/50	Continuous	40/60	22/78	Unknown	Continuous	Continuous
Sprinkle format	Yes	Dissolvable in water	Yes	No	Unknown	No	No
Available doses	6	5	8	4	4	7	4
Abuse potential	Low	Very low	Low	Very low	Likely high	None	None
Controlled substance	Yes	Yes	Yes	Yes	Yes	No	No

*Clinical experience indicates that, for some patients, duration of effect is shorter or longer than what is indicated in the product monograph.